The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eason Lee - Needham & Company - Analyst
: Great. Thanks so much, Meg, for the awesome presentation. Maybe touch upon each of your programs, just some quick hits on these, but on
soticlestat, I think you don't have the slide showing the efficacy that you saw, the reduction in seizure frequency in the Phase 2s. I guess, how does
that compare to the existing products that we have on the market?
Question: Eason Lee - Needham & Company - Analyst
: Got it. And then I guess, I think for the Phase 3, I think there was about 142 patients in Dravet, 234 in LGS. Just remind me like how does that compare
to the sample sizes that you inaugurated in the Phase 2s?
Question: Eason Lee - Needham & Company - Analyst
: Got it. Understood. Let's go to 329, and I guess how much lower do you think you can take the dose relative to Sabril, maybe achieving the, kind
of, your desired therapeutic effect? I mean, I guess that's really what your Phase 1 is trying to answer, but maybe what's your initial inclinations
there?
Question: Eason Lee - Needham & Company - Analyst
: Right. And then I guess, outside of what, I guess, Sabril is being used for, THC, infantile spasms. I'm sure people studying vigabatrin in a whole host
of additional indications, but ultimately, right, unable to find the right therapeutic dose. Maybe what are these other indications that vigabatrin is
being assessed for and maybe which ones do you think could be more -- could be maybe be more up front and center from -- for what you could
develop with 329, maybe further down the line.
Question: Eason Lee - Needham & Company - Analyst
: All right, understood. Maybe if we go to 350, so it sounded like, I think, based on your comments that, that drug developers have tried to develop
KCC2 activator, but I guess have not been successful for, I guess, many different reasons. Sounded like there may be some formulation challenges
or otherwise. Maybe, kind of, curious, how did you guys overcome maybe some of the historical challenges to what you believe will can be a very
compelling product to bring forward to the clinic?
Question: Eason Lee - Needham & Company - Analyst
: Sounds good. Sounds good. So I see that we're almost out of time. So I think with that, I'll close out the session. Meg, thank you very much for the
presentation and discussion. And thank you very much to the listeners for joining us today.
|
